New Insights into the Diagnosis and Treatment of Hepatocellular Carcinoma

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a primary liver cancer that is highly prevalent worldwide. The management of HCC requires a multidisciplinary approach, with therapy options including surgery, chemotherapy, radiation therapy, and targeted therapy. The choice of therapy depends on several factors, including the stage and extent of the disease, the patient's underlying liver function, and the presence of comorbidities. In recent years, there have been significant advances in the treatment of HCC, with the development of new systemic therapies and targeted molecular therapies. Researchers are exploring different types of immunotherapy for HCC, including checkpoint inhibitors and adoptive cell transfer therapy. Early studies have shown promise for these treatments, with some patients experiencing significant tumor shrinkage and improved overall survival rates. However, there is still a need for better therapies that can improve the outcomes of HCC patients.

We look forward to receiving your contributions.

Dr. Evangelos Koustas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• checkpoint inhibitors
• combinatorial treatments
• hepatocellular carcinoma (HCC)
• immunotherapy
• liver cancer
• therapy
• targeted therapy